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Abstract
Tryptophan-rich proteins from several malarial parasites have been identified where they play an important role in host-
parasite interaction. Structural characterization of these proteins is needed to develop them as therapeutic targets. Here, we
describe a novel Plasmodium vivax tryptophan-rich protein named PvTRAg33.5. It is expressed by blood stage(s) of the
parasite and its gene contains two exons. The exon 1 encodes for a 23 amino acids long putative signal peptide which is
likely to be cleaved off whereas the exon 2 encodes for the mature protein of 252 amino acids. The mature protein contains
B-cell epitopes which were recognized by the human immune system during P.vivax infection. The PvTRAg33.5 contains 24
(9.5%) tryptophan residues and six motifs whose patterns were similar among tryptophan-rich proteins. The modeled
structure of the PvTRAg33.5 consists of a multidomain architecture which is stabilized by the presence of large number of
tryptophan residues. The recombinant PvTRAg33.5 showed predominantly a helical structure and alpha helix to beta sheet
transition at pH below 4.5. Protein acquires an irreversible non-native state at temperature more than 50uC at neutral pH. Its
secondary and tertiary structures remain stable in the presence of 35% alcohol but these structures are destabilized at
higher alcohol concentrations due to the disturbance of hydrophobic interactions between tryptophanyl residues. These
structural changes in the protein might occur during its translocation to interact with other proteins at its final destination
for biological function such as erythrocyte invasion.
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Introduction
Malaria remains uncontrolled to date and requires effective
antimalarial drugs and vaccines [1]. Both, vaccine and drug
development strategies require identification and characteriza-
tion of the target molecules. The parasite molecules which
interact with the host molecules are good drug or vaccine
targets. This is because any molecule or antibody which can
disrupt this host - parasite molecular interaction can be used as
therapeutic reagent to interrupt the disease progression.
Enormous efforts are therefore being made to identify such
parasite molecules. However, in comparison to the Plasmodium
falciparum, only fewer vaccine/drug target molecules of P.vivax
have been identified because of its non-cultivable nature
although this parasite affects large number of people in tropical
countries and sometime can cause severe complications in
humans [1,2,3].
Tryptophan-rich proteins from several Plasmodium species
have been identified. They play an important role in the
host-parasite interaction [4,5,6,7,8]. Some of them may be
involved in reinvasion of the host erythrocytes by the parasite
[5]. The synthetic peptides derived from the P.falciparum
tryptophan-threonine rich antigen (PfTryThrA) were able to
inhibit the invasion of the erythrocyte by the merozoite [9].
These proteins across the malarial species contain positional
conservation of the tryptophan residues which could be
functionally important for the parasite. The P. vivax genome
encodes for more number of such tryptophan-rich proteins than
any other malarial species (http://www.plasmodb.org). These
proteins need to be characterized so as to develop them as the
drug or vaccine targets. Recently, we have described immuno-
logical characterization of some of these P.vivax proteins and
reported that they were highly immunogenic in humans
[10,11,12,13,14]. The tryptophan-rich domains of all these
proteins were also conserved in the parasite population.
Unfortunately, so far none of the tryptophan - rich antigen of
any of the Plasmodium species has been structurally character-
ized. Here, we describe cloning, expression, human humoral
immune response, physico-chemical characterization and mo-
lecular modeling of a novel 33.5 kDa P. vivax tryptophan-rich
protein called PvTRAg33.5 which showed a significant
homology to the PfTryThrA of P.falciparum.
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Reverse transcription PCR
Previously isolated RNA from the P.vivax - infected blood was
used for a two step reverse transcription PCR with oligodT
primers and random decamers using RETROScriptH (Ambion,
Inc. Austin, TX USA) as per the manufacturer’s instructions. The
exon 1 and part of the exon 2 was amplified from the cDNA as
well as the genomic DNA (to detect intron) using the gene specific
primers F1 (forward) (59-ATGGTTGCCTTATTACCAATTT-
CA-39) and R1 (reverse) (59-AGTTTTCCCAGTCAGCATCA-
TTCC-39). A 2 mL of 1:5 dilution of the primary PCR product
was used as a template for the semi-nested PCR using primers F2
(59-TCTGCGGCTTACCTTTTAAGCAAC-39) and R1 (men-
tioned above). A 50 mL PCR reaction mixture included the Taq
DNA polymerase (1U) with 1X PCR buffer, 0.5 mM dNTPs,
1.5 mM MgCl2, 0.5 mM of each primer and 10 ng of the template
DNA. A control reaction was also included in which no reverse
transcriptase was added to rule out the possibility of the DNA
contamination after DNase treatment in the cDNA synthesis. The
PCR cycling conditions included initial denaturation at 94uC for
5 min followed by 35 cycles of denaturation at 94uC for 30 sec,
annealing at 56uC (for F1 and R1) or 58uC (for F2 and R1) for
30 sec and extension at 72uC for 30 sec. Final extension was
carried out at 72uC for 5 minutes. The amplified products were
purified from the gel using AccuPrepH gel purification kit (Bioneer
Corporation, korea) and sequenced from both the strands using F2
and R1 primers on the ABI Prism A310 Genetic Analyzer (PE
Applied Biosystems, CA, USA) as described before [15].
Cloning, expression and purification of the recombinant
PvTRAg33.5
The exon 2 of pvtrag33.5 gene was PCR amplified from the
P.vivax DNA using primers, 59-TGTAGTCGACTCAAAGCG-
CAGTAG-39 (forward) and 59TTGTTCCTAATTGAGTCTA-
GAATTCC39 (reverse) having SalI and XbaI sites (underlined)
respectively. The cycling parameters for PCR included initial
denaturation at 94uC for 5 minutes followed by 35 cycles of
denaturation at 94uC for 15 sec, annealing at 55uC for 30 sec,
extension at 68uC for 1 minute and final extension at 68uC for 15
minutes. The PCR product was cloned into the pGEMT vector
and sequenced with the universal primers. The fragment was
transferred to the expression vector pPROExHT b (Invitrogen
Life Technologies, Carlsbad, CA, USA). The recombinant
PvTRAg 33.5 was expressed in E.coli BL21 (DE3) codon plus-
RP and induced with 1 mM isopropyl-b-D-thiogalactopyranoside
(IPTG) at 22uC for 4 hours.
The recombinant protein from the culture pellet was purified
using the Immobilized Metal Affinity Chromatography on the
Ni
2+ NTA agarose column according to the manufacturer’s
instructions (Qiagen, GmbH, Hilden, Germany). It was further
purified by the Anion Exchange High Performance Liquid
Chromatography (Biologic Duo flow, Biorad laboratories, Hercu-
les, CA, USA). The dialyzed Ni
2+ NTA purified protein was
injected in 50 ml sample loop from where it was loaded on to the
top of 1.3 ml UNO Q1 Anion exchange column (Biorad
laboratories, Hercules, CA, USA) which had been pre-equilibrated
at a flow rate of 2 ml/minute with ten column volumes of buffer A
(20 mM Tris, pH 8.0). The bound proteins were then eluted by
the NaCl gradient (0–500 mM) by employing buffer B (20 mM
Tris pH 8.0 and 0.5 M NaCl) at a flow rate of 2 ml/minute over a
period of ten minutes. One ml fractions each were collected and
detected at a wavelength of 280 nm by the deuterium lamp in the
Quad Tec UV-Vis detector integrated with the HPLC unit. The
homogeneity of the purified recombinant PvTRAg33.5 protein
was confirmed by the SDS-PAGE as described earlier [15].
Direct binding Enzyme-Linked Immunosorbent Assay
(ELISA)
The ELISA was performed as described earlier [15,16] using 50
P. vivax-infected and 39 uninfected sera samples at a 1:100 dilution
and 100 ng of the purified recombinant PvTRAg33.5 protein. The
goat anti-human IgG horseraddish peroxidase conjugate at a
1:400 dilution (Pierce Chemical Company, Rockford, IL, USA)
was used as secondary antibody. The mean OD plus 3 standard
deviations of the normal healthy controls was used as the cutoff
value for a positive response.
Physico-chemical characterization of recombinant
PvTRAg33.5
All the measurements were carried out at the room tempera-
ture, unless stated. The concentration of protein samples were
determined spectrophotometrically from the extinction coefficient
reported at 280 nm.
Circular dichroism measurements. The circular dich-
roism (CD) was measured with a JASCO J-815 spectropolarimeter
calibrated with ammonium d-10 camphorsulfonate. A cell of path
length 0.1 cm was used for scanning between 250–195 nm and a
cell of path length 1.0 cm was used for scanning between
300–250 nm. The results were expressed as the mean residue
ellipticity (MRE) in deg.cm
2.dmol
21, which is defined as:
MRE~hobs mdeg ðÞ = 10|n|Cp|l ðÞ ð iÞ
Where hobs, is the observed ellipticity in degrees, n is the number
of peptide bonds per molecule, Cp is the molar concentration, and
‘l’ is the length of light path in cm. The a-helical content of
proteins was calculated from the MRE value at 222 nm (MRE222)
using the following equation [17]:
Percent a-helix~ MRE222{2340 ðÞ =30300 ½  |100 ðiiÞ
CD data have also been analyzed by online available software,
K2d [18].
Fluorescence measurements. The fluorescence spectra
were recorded with a Hitachi F-3500 spectrofluorophotometer in
a 1.0 cm path length quartz cell. Samples containing different
concentrations of the organic solvent were equilibrated at room
temperature for 30 minutes before recording of the fluorescence
measurements. The excitation wavelength was 295 nm and the
emission was recorded from 300 to 400 nm. The ANS (8-anilino-
1-naphthalene-sulfonate) binding was measured by fluorescence
emission with excitation at 380 nm and emission was recorded
from 400 to 600 nm. Typically, the ANS concentration was 50
times excess of protein concentration (7 mM).
Sequence analysis
The PvTRAg33.5 full length sequence was analyzed using
signal prediction servers, Ipsort [19], and SOSUI [20] utilizing
different prediction methods to determine the presence of the
signal peptide region. The transmembrane helical region analysis
of the PvTRAg33.5 (exon2) was carried out using TMHMM [21]
and TM Pred [22] servers. InterPro scan and ProScan [23]
analysis was carried out for the motif and/or the pattern
prediction. The 91 similar sequences obtained from the PlasmoDB
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to the identify conserved domain, aligned in MAST [25] and fed
into meta-MEME [26]. These motifs were then combined into a
single, motif-based Hidden Markov Model (HMM) and used for
searching homologs. The complete sequence of the PvTRAg33.5
was used for the identification of motifs.
Secondary structure prediction
The prediction servers incorporating different algorithms were
used for the secondary structure prediction to minimize the error
in prediction (supplementary material S1). The consensus
secondary structure was derived employing the probability of the
predicted sequence and the type of secondary structure prediction
from these methods. This was compared with the data derived
from the experimental CD studies.
Model development and verification
The initial step for the model development is the identification
of a structural homology. Threading technique or fold recognition
that assign folds to target sequences with very low sequence
identity to known structures can also be employed for the template
generation. The threading servers utilized to build initial models
included PHYRE [27], Fugue [28], PredictProtein [29], SAM-
T08 [30] and iTASSER [31,32,33]. These servers exploit various
machine learning fold recognition techniques like recognizing
distant homologues by sequence-structure comparison, profile-
profile alignments and protein folding potentials. The final
templates so obtained were used to build a homology model with
Discovery Studio v1.7 (www.accelrys.com). Energy minimization
of generated model was by CHARMm [34] force field, a implicit
distance-dependent dielectric constant and a non-bonded atom
cut-off 12 angstrom, by the Adopted Basis Newton-Raphson
energy minimization. Two thousand steps of energy minimization
of r.m.s. gradient of 0.05 Kcal/(mol6Angstrom) was performed.
The model was checked for its accuracy and correctness by the
Ramachandran plot to determine the amount of misplaced phi
and psi angles. The stereochemical environment, the conforma-
tion of the backbone and side chains was analysed using
PROCHECK [35].
Molecular Dynamics
The overall stability of the PvTRAg33.5 model was checked by
a molecular dynamics simulation using the CHARMm [34]
module on a fully hydrated model. In the first step of energy
minimization, the backbone of model was kept flexible. The
minimized, hydrated complex was then subjected to a molecular
dynamics simulation in three stages. In the first stage, the
temperature of the system was raised from 0 to 300 K for 2 pico
sec. The system was then equilibrated for 20 sec, and the final
production run was carried out over another 100 picoseconds.
Accession numbers
The nucleotide sequences described in the paper have been
deposited in the Genbank under the accession numbers FJ481116
for the genomic DNA and FJ481117 for the cDNA derived from
the pvtrag33.5 gene of the Indian P.vivax isolate.
Results
Sequence analysis of the pvtrag33.5 gene
Homology searches for the tryptophan-rich antigen of P. vivax
identified a number of related protein molecules in the
Plasmodium database (http://www.plasmodb.org). We selected a
protein named here as PvTRAg33.5 which is of 33.5 kDa mol.
wt and rich in tryptophan residues. This protein showed
maximum homology of 56% (33% identity) with the
PvTRAg35.2 of P.vivax (Fig. S1). Its sequence homology with
the P.falciparum and P.yoelii tryptophan rich proteins PfTryThrA
and PypAg3 was 55% (30% identity over a 43-275 aa overlap)
and 51% (29% identity over a 20-270 aa overlap), respectively.
Twenty out of 24 tryptophan residues of PvTRAg33.5 were
positionally conserved among these proteins. Several tryptophan
residues were posionally conserved across the tryptophan-rich
proteins of Plasmodium species (Fig. S1). The pvtrag33.5 gene
contains two exons of 69 bp (exon-1) and 756 bp (exon-2). The
exon 1 encodes for a putative signal peptide which is likely to be
cleaved away and thus may not be part of the mature folded
protein. Hence, only the exon2 encoded protein was used for
further characterization and model determination. The ProScan
analysis found one putative glycosylation site (Asn 81) and eight
putative phosphorylation sites (Ser 4, Ser 98, Thr 129, Ser 177,
Thr 179, Ser 217, Ser 243 and Thr 232). The sequences input
to MEME yielded the presence of seven different motifs in the
full length sequence (Table 1). The tryptophan-rich proteins
having more than 30% identity contained all 7 motifs in the
order ‘M7 M3 M6 M1 M4 M5 M2’. A database search using
these clusters with MAST package also did not yield any
significant match indicating the absence of orthologues for
PvTRAg33.5.
Expression and purification of the recombinant
PvTRAg33.5
We were unable to express the complete cDNA of the pvtrag 33.5
gene in E.coli and thus decided to express the exon 2 coding region
and discarded exon 1 as it encodes only for the putative signal
peptide which may not be part of the mature protein. The exon 2
encoded protein was found in the inclusion bodies (90%) as well as
in the soluble fraction (10%). In order to avoid the in-vitro
refolding process, we purified the recombinant protein from the
soluble fraction. The recombinant protein was purified on the Ni
2+
NTA agarose column since the expressed protein contained the
His tag. Although the protein was purified to a great extent by this
column, the minor contaminants were still present in the
preparation (lane3 in Fig. 1). These contaminants were removed
by the HPLC using an anion exchange column where this protein
eluted as a single peak between 440 and 500 mM NaCl
concentration (data not shown). This peak was found to contain
only a single band of 33.5 kDa on 12% SDS-PAGE (lane 4 in
Fig. 1).
In vivo expression of the PvTRAg33.5 by P. vivax
Since the pvtrag33.5 gene was not annotated in the PlasmoDB
sequence database at the time of initiating this work, we wanted
to know if this gene was actively expressed by the parasite. The
RT-PCR results revealed the presence of the pvtrag33.5 gene
transcript in the parasite (Fig. 2a). The size difference between
the cDNA and genomic DNA PCR products not only confirmed
the specificity of the RT-PCR but also established the presence of
an intron in the gene (Fig. 2a). The sequence analysis of the RT-
PCR product and its comparison with the genomic DNA
sequence revealed that the size of the intron was 184 bp and
the consensus splice site sequence GU/AG at the intron-exon
junction (Fig. 2b). That this pvtrag33.5 gene transcript was
translated in to the protein product in the parasite was evident
from the fact that majority of the P.vivax patients produced
antibodies against PvTRAg33.5 during the acute phase of
infection (described below).
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polypeptide of PvTRAg33.5 among a P.vivax infected
individuals
The natural humoral immune response to the PvTRAg33.5 was
confirmed by assessing the reactivity of the exon-2 derived
recombinant protein with the antibodies present in each sera sample
by the ELISA. The positive responders were defined as those who
exhibited an OD495 higher than 0.55 (mean +3 SD of control sera).
Forty seven of the 50 serum samples (seropositivity 94%) from the
P.vivax infected individuals gave an OD above this cutoff (Fig. 3). The
mean 6SD values of OD for the P.vivax infected and naive individuals
were 1.0460.39 and 0.2560.10, respectively. All individuals had
different levels of serum antibodies to the PvTRAg33.5.
Physico-chemical characterization of the PvTRAg33.5
Effect of pH. Studies of the far UV CD can be used to
quantitatively assess the overall secondary structure content of the
protein, as the absorbing group is principally the peptide bond.
Figure4ashowsthefarUVCDofthePvTRAg33.5atneutraltolow
pH. The UV CD spectrum at pH 7.2 shows minima between 208
and 222 nm, a characteristic feature of the a-helical proteins [36].
Interestingly, the protein did not show any loss of the secondary
structure till pH 4.5, but further decreasein pH resulted inthe alpha
helix to beta sheet transition with a single negative minima near
215 nm and a positive ellipticity at 197 nm [37]. Further, the
formation of an isobestic point at 197 nm also indicates the same
[38]. Similar results were also observed with increased ammonium
sulfate (see section 3.5.3) and ethanol (section 3.5.4) concentrations.
The tryptophan residues excite exclusively above 295 nm and
emit in the range of 300 to 400 nm [39]. Figure 4b shows the shift
in wavelength of maximum intensity (lmax) as a probe for the
tertiary structure of the protein against pH. It shows an increase in
lmax as pH decreases, indicating an increase in the polarity of the
tryptophan microenvironment, and thus increases in solvent
accessibility to the core of the protein.
The hydrophobic dye, 1-anilino-8-nephthalene sulphonate
(ANS), is used as a probe to determine the concentration of solvent
accessible hydrophobic patches [40]. The fluorescence of protein-
ANS complex showed no significant change as pH decreased from
7.3 to 3.6, but it was followed by an increase in the ANS binding
with decrease in lmax (Fig. 4c; inset) as pH decreases from 3.6 to 1.6
(Fig. 4c). The results show that the PvTRAg33.5 has lost its
secondary and tertiary contacts to a significant level below pH 3.6.
Effect of temperature. To understand the stability of the
tertiary structure of PvTRAg33.5, we have observed change in
tryptophanyl fluorescence maxima (at 340 nm) as a probe for
tertiary structure, against increase in temperature (Fig. 4d). The
fluorescence intensity has decreased with increase in temperature
from 20–45uC, followed by a sudden increase up to 55uC, and
then a decrease till 80uC. But on cooling, the increase in
fluorescence intensity did not crawled back in the same track
below 50uC, indicating the protein might have been trapped in
some non-native conformation. The change in lmax seems to
support the fact that on heating the lmax increased from 339 to
344 nm as temperature increased from 20 to 80uC, showing
increased accessibility of the hydrophobic tryptophan residues in
solvent due to unfolding. But on reversing the temperature below
80uC, no significant change was observed, indicating entrapment
of the protein molecules in local minima of folding.
Effect of ammonium sulfate. Effect of ammonium sulfate
(0–90 mM) on PvTRAg33.5 has been observed by the far UV CD
and the tryptophanyl fluorescence at different concentration of
ammonium sulfate at pH 7.0 (Fig. 4e). The far UV CD spectra of
the PvTRAg33.5 have shown minima at 208 and 222 nm, a
characteristic feature of the a-helical structure. Increase in the a-
helical structure was observed as salt concentration increased from
Table 1. Motifs identified from MEME present in the various Plasmodium species.
Motif No Motif regular expression Motif in PvTRAg33.5
M1 YKS[ND]ILKKSSTW[DN][DE]S[QE]W[EK]EW[IM]KTEGKE[LF][MLI] YKNYLLKKSEKWNDADWENWANTEMVAHL
M2 [FY]NEWM[ED]SF[IV]NKWI[KN]EK[QK]WNVW YSTWRNDFINRWVSEKKWNSI
M3 WKNNEW[KN][NK]W[MK]KKLEx[DE]WKxFN WKDNEWHNWKLKLEEDWDSFS
M4 WI[QK]WKNxKIx[ES]WL[MS]S[DE]WKxEEDEYWSKW WNQWQHDKMSSWLSSDWKKVGAMYWDLQ
M5 xKW[KN]ERIN[RK]ExE[EQ]WxNWVKxKENx[YF] IKWNDRNARENIEWSKWVQNKEYFI
M6 KEK[ED][WL][EN]EW[LI]Kx[ML][EQ]NKWMH[YF]NE KTDELNGWLNLEENKWNNFSG
M7 VSxLxIxLFLLSSAF VALLPISFFSLSAAY
doi:10.1371/journal.pone.0016294.t001
Figure 1. Purification of recombinant PvTRAg33.5. SDS-PAGE
profile of the purification steps. Uninduced and induced culture pellets
of the recombinant clone were solubilized in the loading buffer and
loaded in lane 1 and 2, respectively. The Ni
2+ NTA column purified
preparation was loaded in lane 3. Lane 4 contains the HPLC purified
protein. Size of protein bands in the marker lane (M) is indicated on left
hand side. The recombinant PvTRAg33.5 band is indicated by an arrow.
doi:10.1371/journal.pone.0016294.g001
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PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16294Figure 2. In vivo expression of the pvtrag33.5 gene. a) Detection of the pvtrag33.5 gene transcript by Reverse Transcription PCR. PCR
amplification of the P.vivax cDNA (Lanes 1–4) and genomic DNA (Lane 5) using pvtrag33.5 gene specific primers. RT- PCR product of pvtrag33.5
specific cDNA synthesized using oligodT (Lane 2) or random decamers (Lane 4) with gene specific primers. Reverse transcription negative control
using oligodT (Lane 1) or random decamers (Lane 3) as primers for cDNA synthesis. Lane 5: PCR product of genomic DNA amplification, and Lane
6: 100 bp ladder. PCR product sizes are indicated by arrows. b) Sequence alignment of PvTRAg33.5 genomic DNA and cDNA. Splice site sequence is
shown in bold letters. Dashes indicate the absence of nucleotides. Numbers on the right-hand side indicate the number of nucleotides.
doi:10.1371/journal.pone.0016294.g002
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tryptophanyl residues of the PvTRAg33.5 at different salt
concentrations. The increase in fluorescence on addition of the
salt indicates opening of the hydrophobic tryptophanyl residues
towards the polar solvent. From the far UV CD and fluorescence
experiments, we may conclude that increase in salt concentration
has disrupted the tertiary structure of the protein without
destabilizing its secondary structure.
Effect of ethanol. Alcohols can be used as a model for
plasma membrane [41]. Some of the tryptophan-rich proteins are
found to get anchored to the RBC membrane [4,5]. We have
checked the effect of ethanol on the PvTRAg33.5 by the far UV
CD and tryptophanyl fluorescence spectroscopy to study the effect
of hydrophobic environment on the protein conformation. Fig. 4f
shows stabilization of the secondary and tertiary structure (inset) in
the presence of 0 to 40% and 0 to 35% ethanol respectively. But
further increase in the alcohol concentration disrupts the tertiary
as well as secondary structure.
Secondary structure and molecular model of the
PvTRAg33.5
The secondary structure prediction studies show that the exon 2
encoded polypeptide predominantly comprises of helix and coil
regions. A consensus secondary structure prediction sequence was
drawn from the results of the different secondary structure
prediction servers (Fig. S2). In this, the sequences of each and
every amino acid position was assigned either helix or coil or
extended sheets only when at least 50% of the above web servers
predicted the similar secondary structure. The consensus second-
ary structure prediction showed that the PvTRAg33.5 has 76.2%
helix and 23.8% coil with no extended sheets. This helical content
derived from the analysis was more than that of the above
mentioned experimental CD data.
In the absence of a clear structural homologue from PDB or
pattern prediction, knowledge-based approach to structure
prediction employing the fold recognition and protein threading
methods was undertaken to determine computationally a suitable
template model for the exon 2 encoded polypeptide. The results
from the diverse threading servers were compiled and analyzed to
derive possible templates based on a three-fold criterion. Models
predicted with less than 60% accuracy, comprising short segments
of fewer than 90 amino acid residues and structures consisting
mainly of b-sheets were not included as these contradicted both
experimental and secondary structure consensus data. Several
models were built using the templates so obtained (PDB Ids: 2c5k,
1is1, 2a2f, 2lis, 1zro, 2bs5, 2hsb, 2pe4, 2c6j, 1u4q, 2j68 and
Figure 3. Seroreactivity of recombinant PvTRAg33.5 among P.vivax exposed individuals. ELISA was performed with 50 sera form P. vivax
patients (a) and 39 from unexposed healthy controls (b) by coating 96-well microtitre ELISA plates with the purified recombinant PvTRAg33.5. Each
bar represents the OD value for the individual serum. Pp: pooled patient sera; Np: pooled sera from healthy controls.
doi:10.1371/journal.pone.0016294.g003
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Studio v1.7. The loops were built using the LOOPREFINE-
MENT module. A high quality model was selected based on the
probability density function (PDF) calculated by the program. The
PDF is derived from spatial restraints while building the model
and identifies regions of high energy. The final model showed
Figure 4. Physico-chemical characterization of PvTRAg33.5. Far UV CD spectra at different pH (a), emission wavelength at maximum intensity
after exciting it at 295 nm as a function of pH (b), fluorescence intensity (filled circle) and emission wavelength at maximum intensity (empty circle)
(inset) of ANS-protein complex as a function of pH, after exciting it at 380 nm (c), fluorescence intensities and emission wavelength maxima (inset)
after exciting at 295 nm as a function of increase in temperature (empty circle) and consecutive decrease in temperature (filled circle) at pH 7.0 (d),
far UV CD spectra and fluorescence intensities (inset) in the absence and presence of different ammonium sulfate concentrations at pH 7.0 after
excited at 295 nm (e), and far UV CD spectra and fluorescence intensities (inset) in the absence (N) and presence of different ethanol concentrations
after exciting at 295 nm (f) of PvTRAg33.5.
doi:10.1371/journal.pone.0016294.g004
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PHYRE. The stereochemistry of the final model was checked
with the program PROCHECK [35].
The refinement of the model with special emphasis on the loops
was carried out using molecular dynamics simulation. The total
energy and simulation temperature were found to remain steady
with little fluctuation (Table 2). In addition to this the maximum
r.m.s. deviation was observed to be 0.6 A ˚. Hence, the results from
the molecular dynamics simulation indicated that the modeled
structure is stable.
Discussion
For the first time, we describe here the structural characteristic
features of a tryptophan- rich antigen (PvTRAg33.5). This protein
is not a membrane integrated protein, it lacks cysteine residues,
and it is soluble in nature. The tryptophan residues are distributed
over the entire length of the mature protein (encoded by exon 2)
which may influence the folding of the protein in the absence of
the cysteine residues. Thus, the three dimensional conformation of
the protein is most probably constrained by the number and
hydrophobic nature of these tryptophan residues. The tryptophan
residue is conserved in the motifs, however, a great deal of
variability is observed for adjacent polar and hydrophobic
residues. Despite the absence of orthologues, the profile HMM
analysis clearly indicates the presence of similar motifs in the
Plasmodium species. In non malarial proteins, the tryptophan rich
domains have been reported in a variety of the transmembrane
surface proteins which play an important role in the folding and
assembly [42].
The modeled tertiary structure of the protein consists of three
domains (Fig. 5). The subdomain 1 comprising residues 1–28
adopts a random coil structure except for a two turn helix (H1), the
subdomain 2 spanning residues 30–113 has 2 long (H2 and H3)
and 2 short helices and the subdomain 3 stretching from residues
126–252 consists of three long helices (H6, H7: and H8). A long
loop of 16 residues connects helices 6 and 7 whereas helices 7 and
8 are anti-parallel and are joined by a short loop of 5 residues. The
subdomains 2 and 3 are associated by a 12 amino acid long
flexible linker region. The linker region adopts a random coil
structure and permits different orientations of the subdomains 1
and 2 as regards to the third subdomain. The motifs, M2-M7,
identified from MEME have helical structures. The subdomain 3
participates in numerous hydrogen bonds and van der Waals
interactions with subdomain 2 while these are limited to the tail
residues to subdomain 1.
Thus the PvTRAg33.5 protein belongs to the proteins from the
all-alpha class with no identical fold in Structural Classification of
Proteins (SCOP) database [43]. The closest structural similar fold
in SCOP was observed to be the Duffy binding like domain (DBL)
fold which has earlier been observed in P. knowlesi (PDB Id: 2C6J)
[44] and P. falciparum (PDB Ids: 3CML [44] 1ZRO and 1ZRL
[45]). The DBL domain possesses two subdomains, each with a
three- helical bundle. The subdomain 3 of PvTRAg33.5 has a 3
helix bundle comparable to the DBL domain but a structural
superimposition of the long helices of this sub domain revealed
that the position of the helices with respect to each other are
dissimilar. The main difference is observed in the subdomain 2. A
structural superimposition along the long helix H6 of the
subdomain 3 indicated that the orientation and positioning of
the subdomains 2 and 3 was different with respect to each other in
these proteins. These differences indicate that the linker region
connecting the subdomain 2 and 3 is flexible and a conformational
change can alter their relative orientations.
The CD data indicates that the PvTRAg33.5 has nearly 50% a-
helix structure which was also predicted by the secondary structure
prediction analysis. However, the protein has shown a total loss of
the alpha helical structure if pH was decreased below 4.5. Such
structural change from the alpha helical to the beta sheet and vice-
versa has been reported in various systems, for example, the beta
sheet structure of the HIV’s gp120 gets converted into the alpha
helix when virus binds to the host membrane protein CD4 [45–
49]. The PvTRAg33.5 protein, however, remains stable upto
pH 4.5 or till 50uC at pH 7.0. Even 40% ethanol could not disrupt
its secondary structure. These evidences suggest that the protein is
stable enough to withstand some environmental stresses up to
certain extent.
The PvTRAg33.5, probably being a small polypeptide, has two
state transitions in its secondary structure under the denaturing
conditions. The PvTARAg55, probably being a longer polypep-
tide [12], seems to be more resistant to the effect of low pH than
the PvTRAg33.5 (Data not shown). In short, the PvTRAg33.5 is a
predominantly a-helical but a loss of the structure occurs under
severe environmental stressed conditions. Under stress, either
more number of the tryptophan residues gets exposed or the
similar number of tryptophan residues exposed with larger extents,
as indicated by the tryptophan fluorescence under low pH, high
temperature and high concentration of the salt or the non polar
solvent. The tryptophan rich regions appear to be critical for the
cell-cell fusion activity of the trans-membrane glycoproteins [46].
In nature, certain external stimuli may also cause the structural
changes in the proteins leading to the diseased conditions [47]. For
example, binding of the ligands could trigger the conformational
changes in some of the Trypanosomal enzymes to modulate their
activity leading to the disease pathogenesis [48,49]. The structural
perturbation of the PvTRAg33.5 may, therefore, connect with its
biological function such as its probable role in the erythrocyte
invasion. The Tryptophan residues have also been shown to play
an important role in protein-protein interactions and signal
transduction [50,51,52,53,54,55]. There are rapidly mounting
evidence that the proteins must at least partly unfold in order to be
translocated across a biological membrane. The precursor proteins
are found to unfold before or at the time of their transport across
the membranes [56].
In conclusion, for the first time the structural characteristic
features of a Plasmodium tryptophan-rich protein are described
here. The PvTRAg33.5, a novel tryptophan-rich antigen from
P.vivax, is expressed during the blood stage of the parasite, has a
predominantly a-helical structure, and its secondary structure
is lost upto 50% under the stressed conditions which may also be
faced by the parasite in its host. The modeled structure has
three domain architecture and this conformation is stabilized
by the presence of a large number of tryptophan residues which
in the absence of disulphide bonds influence the folding due
Table 2. Molecular Dynamics simulation.
Time (ps)
rmsd w.r.t to first
conformer (A ˚)
Potential Energy
(kcal/mol) Temp (K)
00 2570.36 303
25 0.56 2566.30 306
50 0.59 2568.31 302
75 0.59 2569.15 301
100 0.60 2570.04 302
doi:10.1371/journal.pone.0016294.t002
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16294Figure 5. Model of PvTRAg33.5 structure. a) Model of PvTRAg33.5 structure which has three subdmains: subdomain 1 (blue), subdomain 2 (red),
subdomain 3 (green) and a linker (yellow) region. The helices are represented as cylinders and the coiled structure as loops. Subdomain 1 adopts a
random coil structure except for a two turn helix from residues 16–25 (H1). The second subdomain has 2 long (H2: 29–54 and H3: 60–80) and 2 short
helices (H4: 89–98 and H5: 104–113) connected by three loops. The subdomain 3 consists of three long helices (H6: 126–162, H7: 177–213 and H8:
217–244). The tryptophan (Trp) residues in the helices are drawn in ball-and-stick and assigned the helix color. b) The three dimensional model of
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PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e16294to their predominantly hydrophobic nature. Furthermore, the
PvTRAg33.5 contains B-cell epitopes which are highly conserved
in the parasite population and high antibody response is being
generated in humans during P.vivax infection. Further studies are
required to define the biological function of this protein in the
parasite.
Supporting Information
Figure S1 Multiple sequence alignment of PvTRAg33.5
(Plasmodb ID: PVX_121897) with close tryptophan rich
homologs present in Plasmodium species. The sequences
of these proteins were retrieved from the Plasmodium database
(www.plasmodb.org) and aligned using ClustalW software at
http:/www.ebi.ac.uk/clustalW. The plasmodb ID of P.vivax
homologs are PVX_090250 for PvTRAg39.8, PVX_109280 for
PvTRAg35.2, PVX_090265 for PvTRAg, PVX_101515 for
PvTRAg40, PVX_096995 for PvTARAg55, PVX_112655 for
PvTRAg80.6 and PVX_101510 for PvATRAg74. The plasmodb
ID of P.falciparum homologs are PFA0135w for PfMaTrA,
PF08_0003 for PfTryThrA, PF10_0026 for TrpA-3, and
MAL13P1.269 for LysTrpA. The plasmodb ID of P.yoelii
homologs are PY06023 for PypAg1, and PY03625 for PypAg3.
Stars (‘‘*’’) indicate identical amino acids while double (‘‘:’’) and
single (‘‘.’’) dots indicate the conserved and semi-conserved
substitutions, respectively. All tryptophan residues are in boldface.
The positionally conserved tryptophan residues are shaded grey.
Dashes indicate the absence of amino acids. Numbers on the right-
hand side indicate the number of amino acid residue. The
secondary structure elements for PvTRAg33.5 are indicated on
the top of the sequences. The coils are indicated as bold lines and
helices as tubes. The helices are numbered H1 to H8. Alignment is
according to the PvTRAg33.5 amino acids sequence (complete
sequences of all proteins are not shown).
(TIF)
Figure S2 Secondary structure prediction of exon 2
encoded PvTRAg33.5 by webservers and the consensus
secondary structure prediction.
(TIF)
Supplementary Material S1 Secondary Structure Prediction
Servers.
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